Pfizer Updates Registered Securities on NYSE

TL;DR

**Pfizer just filed a routine 8-K updating its listed securities, no big news.**

AI Summary

Pfizer Inc. filed an 8-K on January 30, 2024, to update its registered securities, specifically its Common Stock ($0.05 par value) and 1.000% Notes due 2027. Both are listed on the New York Stock Exchange under trading symbols PFE and PFE27, respectively. This filing is a routine update, indicating no immediate operational or financial changes, but it confirms the company's current capital structure and its compliance with SEC reporting requirements, which is important for investors tracking the company's financial health and transparency.

Why It Matters

This filing confirms Pfizer's listed securities, providing transparency on its capital structure and ensuring compliance, which is crucial for investor confidence and market stability.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material financial or operational information, posing minimal risk.

Analyst Insight

A smart investor would recognize this as a routine compliance filing, not indicative of any immediate operational or financial changes, and would continue to monitor for more substantive news or financial reports.

Key Numbers

• $0.05 — Common Stock Par Value (The stated par value for each share of Pfizer's common stock.)
• 1.000% — Notes Due 2027 Interest Rate (The annual interest rate for Pfizer's notes maturing in 2027.)

Key Players & Entities

• PFIZER INC (company) — the registrant filing the 8-K
• New York Stock Exchange (company) — the exchange where Pfizer's securities are registered
• $0.05 (dollar_amount) — par value of Pfizer's Common Stock
• 1.000% (dollar_amount) — interest rate of Pfizer's Notes due 2027
• 2027 (date) — maturity year of Pfizer's Notes

Forward-Looking Statements

• Pfizer will continue to maintain its listing on the New York Stock Exchange for its common stock and notes. (PFIZER INC) — high confidence, target: 2025-01-30

FAQ

From the Filing

0000078003-24-000017.txt : 20240130 0000078003-24-000017.hdr.sgml : 20240130 20240130080428 ACCESSION NUMBER: 0000078003-24-000017 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240130 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240130 DATE AS OF CHANGE: 20240130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 24575912 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 pfe-20240130.htm 8-K pfe-20240130 0000078003 false 0000078003 2024-01-30 2024-01-30 0000078003 us-gaap:CommonStockMember 2024-01-30 2024-01-30 0000078003 pfe:NotesDue20271.000Member 2024-01-30 2024-01-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 30, 2024 PFIZER INC . (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification No.) incorporation)     66 Hudson Boulevard East 10001-2192 New York, New York (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 212 ) 733-2323 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.05 par value PFE New York Stock Exchange 1.000% Notes due 2027 PFE27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐ Item 2.02 Results of Operations and Financial Condition On January 30, 2024, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for fourth-quarter and full-year 2023. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein. The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1